Neurologic manifestations, such as myoclonus, asterixis, seizures and altered level of consciousness, may be induced in patients with impaired renal function receiving β-lactam antibiotics, which stem in part from drug accumulation because of altered pharmacokinetics. Because of its long half-life and easy penetration into the cerebrospinal fluid, the third generation cephalosporin, ceftriaxone (CTRX), is often chosen to treat patients with end-stage renal disease (ESRD). Here, the authors describe 4 patients with ESRD complicated with bacterial infection and choreoathetosis after the administration of CTRX. Choreoathetosis disappeared without leaving sequelae after CTRX therapy was withdrawn, although the severity and symptom duration varied. To our knowledge, there are few reports on choreoathetosis associated with β-lactam antibiotic administration in patients with kidney diseases. To prevent delayed diagnosis, one should bear in mind that choreoathetosis might occur in patients with ESRD treated with CTRX, when it is given in high or even regular doses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MAJ.0b013e3181ec063b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Oral Trihexyphenidyl Plus Clonazepam Versus Trihexyphenidyl for the Treatment of Dystonia in Children With Dystonic Cerebral Palsy: An Open-Label Randomized Controlled Trial.
Pediatr Neurol
September 2024
Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India. Electronic address:
Background: Trihexyphenidyl and clonazepam are commonly used to treat dystonia in children with cerebral palsy (CP). However, there is a notable gap in the literature when it comes to studies that combine these first-line agents for the management of dystonia.
Methods: This open-label, randomized controlled trial aimed to compare the efficacy of adding oral clonazepam to trihexyphenidyl (THP + CLZ) versus using trihexyphenidyl alone (THP) in reducing the severity of dystonia, as measured by the Barry-Albright Dystonia (BAD) score.
AAV9-Mediated Intrastriatal Delivery of Reduces Hyperlocomotion in Heterozygous R209H Mutant Mice.
J Pharmacol Exp Ther
July 2024
Department of Pharmacology and Toxicology (A.J.R., J.R.L., R.R.N.), Department of Microbiology and Molecular Genetics (A.J.R.), and Nicholas V. Perricone, M.D., Division of Dermatology, Department of Medicine (R.R.N.), Michigan State University, East Lansing, Michigan; Department of Translational Neuroscience (J.R.P., A.C.S., C.J.K., C.E.S.), Michigan State University, Grand Rapids, Michigan; Hauenstein Neuroscience Center, Mercy Health Saint Mary's, Grand Rapids, Michigan (C.E.S.); and Horae Gene Therapy Center and The Li Weibo Institute for Rare Diseases Research (Z.-T.D.O., T.M., A.R.B., M.S.-E.) and Department of Neurology (Z.-T.D.O., T.M., A.R.B., M.S.-E.), UMass Chan Medical School, Worcester, Massachusetts
Mutations in the gene, which encodes the abundant brain G-protein G , result in neurologic disorders characterized by developmental delay, epilepsy, and movement abnormalities. There are over 50 mutant alleles associated with disorders; the R209H mutation results in dystonia, choreoathetosis, and developmental delay without seizures. Mice heterozygous for the human mutant allele ( ) exhibit hyperactivity in open field tests but no seizures.
View Article and Find Full Text PDFThe Dyskinesia Impairment Scale, Second Edition: Development, construct validity, and reliability.
Dev Med Child Neurol
May 2023
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Article Synopsis
- The aim of the study was to develop a shorter, user-friendly version of the Dyskinesia Impairment Scale (DIS-II) for assessing dystonia and choreoathetosis, while evaluating its validity and reliability.
- The DIS-II evaluates these conditions in 11 body regions with fewer videos needed (14 instead of 26) and a reduced number of scoring items (88 instead of 144), while maintaining good construct validity and distinguishing between eight ability levels.
- Overall, the DIS-II improves upon the original scale by providing valid and reliable measures with simpler scoring and better comparison capabilities for clinical practice and research.
Treating mutation-related severe movement disorders with oxcarbazepine: a case report.
Transl Pediatr
September 2022
Department of Neurology, Children's Hospital of Soochow University, Suzhou, China.
Article Synopsis
- Variants associated with epileptic encephalopathies, developmental delays, and movement disorders highlight the need for effective treatments, particularly for GNAO1-related conditions where options are limited.
- A 5-year-old patient with movement disorder and intellectual disability was identified with a GNAO1 variant; after ineffective standard treatments, he showed significant improvement following oxcarbazepine (OXC) therapy.
- This study is the first to report OXC's effectiveness in treating movement disorders linked to GNAO1 mutations, suggesting that it could be a viable alternative to more invasive treatments.
[Autoimmune Encephalitis Triggered by Herpes Simplex Encephalitis: Main Syndrome, Diagnosis, and Treatment].
Brain Nerve
October 2022
Division of Neurology, Department of Medicine, Nihon University School of Medicine.
Autoimmune disorders, such as choreoathetosis and abnormal behavior secondary to herpes simplex encephalitis (HSE), are discussed in this review. These disorders are known to develop without any evidence of HSE relapse, while they respond to immunotherapies such as intravenous corticosteroids. Recent evidence, including a prospective Spanish cohort study of HSE, revealed that autoimmune encephalitis (AE) can be triggered by HSE, which is closely related to several neuronal surface antibodies (NSAs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!